Orexigen Therapeutics Income from Cont. Ops Quarterly
Orexigen Therapeutics Income from Cont. Ops Quarterly Chart
Orexigen Therapeutics Historical Income from Cont. Ops Quarterly DataPro Data Export
There is no data for the selected date range.
About Income from Continuing Operations
Income Statement line item that does not account extraordinary items and discontinued operations. This metric is frequently used because it excludes items that are unlikely to happen the next reporting period.
For instance, if MSFT had five billion in Income, and 2 billion in an exceptional item charge, its income would be a reported 3 billion. Because the exceptional charge is unlikely to be repeated in the next quarter, some investors prefer to see what MSFT's income was BEFORE charges.
View Income from Cont. Ops Quarterly for OREX.
Start Your YCharts Pro Gold Membership.
Access over 100 stock metrics like Beta, EV/EBITDA, PE10, Free Cash Flow Yield, KZ Index and Cash Conversion Cycle.
YCharts Pro is only $49/month, and comes with a 14-day free trial.Get Started Now
Already a YCharts Pro Gold Member? Sign in here.
OREX Income from Cont. Ops Quarterly Benchmarks
|Arena Pharmaceuticals||Go Pro|
|Pernix Therapeutics||Go Pro|
OREX Income from Cont. Ops Quarterly Range, Past 5 Years
|Minimum||Go Pro||Sep 2008|
|Maximum||Go Pro||Jun 2008|
PR Newswire May 17
Fool May 15
Fool May 14